Pharma Focus Asia

Fujifilm Invests US$1.2 billion to Expand Manufacturing Facility in USA


Fujifilm plans to invest US$1.2 billion to open state-of-the-art manufacturing hubs in the United States. 


The expansion will significantly enhance the large-scale production capacity of the global network through its manufacturing hubs in the United States and Europe.

This expansion not only allows for the accommodation of new projects but also positions the site to become one of the largest cell culture biopharmaceutical CDMO facilities in North America upon completion.

As part of the initial investment, the upcoming expansion in large-scale cell culture facilities will include an additional 8 x 20,000 litres (L) mammalian cell culture bioreactors by 2028, supplementing the already planned 8 x 20,000 L capacity for bulk drug substance. 

The investment aims to create 680 more jobs by 2031, bringing the total number of new, highly skilled local positions to 1400.


Name        Fujifilm
Type          Expansion
Budget    US$1.2 billion
Year          2031


magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference